Quantcast

Dr. Reddy’s to Release Q4 and Full Year FY 19 Results on May 17, 2019

Earnings call slated for May 17, 6:00 PM IST / 8:30 AM EDT

HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY)
will announce results for the fourth quarter and full year ended March
31, 2019 on Friday, May 17, 2019 after the Board Meeting.

Summary of Events

         
Event   Date and Time   Medium
Release of financial results   May 17th, after the Board Meeting  

Email, Media, Company website, Business Wire

Press meet presentation

 

Will be available on the Company’s website

 

URL available on Company’s website, www.drreddys.com

Earnings Call   May 17th, 6:00 PM IST / 8:30 AM EDT  

Hosted by the Company (Details below)

Playback of Earnings Call   After the earnings call till May 24th, 2019   Details below
Transcript of the Earnings call   Will be available on the Company’s website  

URL available on Company’s website, www.drreddys.com

Earnings Call

Following the release, the management of the Company will host an
earnings call to discuss the Company’s financial performance. (Dial
In and other details given below)

Play Back

The play back will be available after the earnings call, till May 24th,
2019. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and
Playback Code is 04147.

 
Conference Dial-In Numbers
Universal Access Number:   +91 22 6280 1219

+91 22 7115 8120

Local Access Number:

Available all over India

  +91 70456 71221
International Toll Free Number:   USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above
numbers. The operator will provide instructions on asking questions
before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124)
(NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr Reddy’s operates in markets across the globe. Our Major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may,” “will,” “should,” “expects,”
“plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency/severity of insured loss events,
(ii) mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v)
the impact of acquisitions or reorganization, including related
integration issues.

The company assumes no obligation to update any information contained
herein.

Contacts

INVESTOR RELATIONS
AMIT AGARWAL
[email protected]
(Ph:
+91-40-49002135)

MEDIA RELATIONS
MITALI SARKAR
[email protected]
(Ph:
+91-40-49002121)

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.